Key result
Dabrafenib and necrostatin-1 attenuate doxorubicin-induced cardiotoxicity and tissue injury in preclinical models.
Why the study?
Doxorubicin use is mainly limited by cardiotoxicity involving necroptosis, motivating comparison of the protective effects of the RIPK3 inhibitor dabrafenib and the RIPK1 inhibitor necrostatin-1.
Does dabrafenib or necrostatin-1 attenuate doxorubicin-induced cardiotoxicity and necroptotic signaling in a rat model?
Does dabrafenib or necrostatin-1 attenuate doxorubicin-induced cardiotoxicity and necroptotic signaling in a rat model?
In a preclinical rat model, the RIPK3 inhibitor dabrafenib attenuated biochemical, functional, and histopathological markers of doxorubicin-induced cardiotoxicity to a similar extent as the RIPK1 inhibitor necrostatin-1.
Answers are grounded in this paper and cite their sources.
May support necroptosis inhibition in rat doxorubicin cardiotoxicity; leaves open clinical translation.
Doxorubicin (DOX) is a commonly used antineoplastic agent whose clinical use is mainly limited by its cardiotoxicity. Since necroptosis has been implicated in DOX-induced cardiotoxicity, this study investigated and compared the protective effects of dabrafenib (Dab), a RIPK3 inhibitor, and necrostatin-1 (Nec-1), a RIPK1 inhibitor, targeting two key components of the necroptotic signaling pathway. Thirty-six male Sprague–Dawley rats were divided into four groups: control, DOX, DOX+Dab, and DOX+Nec-1. Coronary perfusion pressure was assessed in isolated hearts using the Langendorff system, while serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels, cardiac malondialdehyde (MDA) levels, histopathological alterations, and the expression of necroptosis-related proteins were analyzed. DOX treatment significantly increased coronary perfusion pressure, serum CK and LDH levels, cardiac MDA levels, and RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL) expression and induced marked histopathological damage. Both dabrafenib and Nec-1 attenuated these alterations and histopathological damage, although the magnitude of their effects varied across the measured outcomes. No significant differences in serum CK or LDH levels were observed between the two treatment groups. Overall, our findings suggest that dabrafenib may attenuate DOX-induced cardiac injury, although its effects on necroptotic signaling remain to be established.
No takes yet. Share an insight, caveat, or question.
Kaya et al. (2026) studied Doxorubicin-induced cardiotoxicity (n=36). Dabrafenib (and Necrostatin-1) vs. Doxorubicin alone, Doxorubicin + Necrostatin-1, and Control was evaluated on Coronary perfusion pressure, serum CK and LDH levels, cardiac MDA levels, histopathological alterations, and necroptosis-related protein expression (RIPK1, RIPK3, MLKL). Dabrafenib and necrostatin-1 both attenuated doxorubicin-induced increases in coronary perfusion pressure, serum CK/LDH, cardiac MDA, and histopathological damage in 36 rats.
Synapse has enriched 10 related papers. Consider them for comparative context: